CD274 and non-small cell lung carcinoma: An anti-TIGIT antibody (tiragolumab) failed to improve PFS when combined with the anti-PD-L1 antibody, atezolizumab, with (for SCLC, SKYSCRAPER-02) [44] or without (for NSCLC, SKYSCRAPER-01) chemotherapy.